Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for <i>TP53</i>-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes - Concepedia

Concepedia

Publication | Closed Access

Eprenetapopt Plus Azacitidine After Allogeneic Hematopoietic Stem-Cell Transplantation for <i>TP53</i>-Mutant Acute Myeloid Leukemia and Myelodysplastic Syndromes

131

Citations

26

References

2022

Year

Asmita Mishra, Roni Tamari, Amy E. DeZern, Michael Byrne, Mahasweta Gooptu, Yi‐Bin Chen, H. Joachim Deeg, David A. Sallman, Phillip Gallacher, Anders Wennborg,

Journal of Clinical Oncology

Abstract

In patients with m<i>TP53</i> AML and MDS, post-HCT maintenance therapy with eprenetapopt combined with azacitidine was well tolerated. RFS and OS outcomes were encouraging in this high-risk population.

References

	Year	Citations

Page 1